Progen Pharmaceuticals Patent Granted In Important Japanese Market 1

ABN 82 010 975 612

PO Box 2403 Toowong
Queensland 4066 Australia
Telephone: + 61 7 3842 3333
Facsimile: + 61 7 3720 9624
www.progen-pharma.com


Progen Pharmaceuticals Patent granted in important Japanese market


Brisbane, Australia, 28th June 2010. The Directors of Progen Pharmaceuticals Limited
(ASX:PGL, NASDAQ:PGLA) today announced the granting of a Japanese patent for the
Preparation and Use of Sulfated Oligosaccharides which includes muparfostat (PI-88).

Progen Pharmaceuticals Limited has an exclusive worldwide license to muparfostat (PI-88)
technology from the Australian National University.

"Japan is an important market for liver cancer and the granting of this patent provides
additional coverage in this key territory," said Sue MacLeman, Chief Executive Officer,
Progen Pharmaceuticals Ltd.

PI-88 is one of a class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-
cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-
tumour activity is based on inhibition of two biological processes angiogenesis (the growth
of new blood vessels) and metastasis (the spread of cancer to other sites) critical to the
growth and progression of cancer.

The patent number is 4514240. The applicant for the patent is the Australian National
University. The date of grant was 21st May 2010 and the patent term is 20 years from April
24th 1996 (date of commencement of patent term), expiring 24th April 2016.
Historically, PI-88 was the result of fully funded research collaboration with Professor Chris
Parish's group at the John Curtin School of Medical Research at The Australian National
University.

ENDS

About Progen Pharmaceuticals Ltd
Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery,
development and commercialization of small molecule pharmaceuticals primarily for the
treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery
and development. Progen has operations in Australia and the United States of America.
www.progen-pharma.com


For more information:
Sue
MacLeman Jo-Anne
Modesti

Chief
Executive
Officer Phillips
Group

+61 7 3842 3333 +61 7 3230 5000
+61 437 211 200







This release contains forward-looking statements that are based on current management
expectations. These statements may differ materially from actual future events or results due
to certain risks and uncertainties, including without limitation, risks associated with drug
development and manufacture, risks inherent in the extensive regulatory approval process
mandated by, amongst others, the United States Food and Drug Administration and the
Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for
clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance
of PI-88, PG11047, PG545, PG562, PG11122, PG11144 and other drugs, future capital needs,
general economic conditions, and other risks and uncertainties detailed from time to time in
the Company's filings with the Australian Securities Exchange and the United States Securities
and Exchange Commission. Moreover, there can be no assurance that others will not
independently develop similar products or processes or design around patents owned or
licensed by the Company, or that patents owned or licensed by the Company will provide
meaningful protection or competitive advantages.